Anti-cancer activity of adamantane derivatives
Grant
US12576048B2
Kind: B2
Mar 17, 2026
Assignee
The Regents of the University of California
Inventors
Andrew Sharabi
Abstract
Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.
CPC Classifications
A61K 31/13
A61K 31/16
A61K 45/06
A61K 47/60
A61P 35/00
A61P 35/02
A61P 35/04
Filing Date
2019-12-05
Application No.
17311101
Claims
17